(0.56%) 5 156.49 points
(0.34%) 38 806 points
(0.53%) 16 242 points
(0.86%) $78.78
(3.31%) $2.21
(1.25%) $2 337.40
(3.22%) $27.55
(0.56%) $970.75
(-0.16%) $0.927
(-0.56%) $10.81
(-0.29%) $0.795
(-0.08%) $91.38
-2.62% HKD 12.66
Live Chart Being Loaded With Signals
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic diseases, and cardiovascular diseases in the People's Republic of China...
Stats | |
---|---|
Volumen de hoy | 3.60M |
Volumen promedio | 2.19M |
Capitalización de mercado | 11.14B |
EPS | HKD0 ( 2024-03-28 ) |
Last Dividend | HKD0.114 ( 2020-09-29 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 5.19 |
ATR14 | HKD0.0140 (0.11%) |
Volumen Correlación
YiChang HEC ChangJiang Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
YiChang HEC ChangJiang Correlación - Moneda/Commodity
YiChang HEC ChangJiang Finanzas
Annual | 2023 |
Ingresos: | HKD6.29B |
Beneficio Bruto: | HKD4.99B (79.21 %) |
EPS: | HKD2.26 |
FY | 2023 |
Ingresos: | HKD6.29B |
Beneficio Bruto: | HKD4.99B (79.21 %) |
EPS: | HKD2.26 |
FY | 2022 |
Ingresos: | HKD3.74B |
Beneficio Bruto: | HKD2.85B (76.00 %) |
EPS: | HKD0.0871 |
FY | 2021 |
Ingresos: | HKD913.79M |
Beneficio Bruto: | HKD483.70M (52.93 %) |
EPS: | HKD-0.667 |
Financial Reports:
No articles found.
YiChang HEC ChangJiang Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
First Dividend | HKD0.0885 | 2016-06-08 |
Last Dividend | HKD0.114 | 2020-09-29 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 9 | -- |
Total Paid Out | HKD2.08 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.09 | -- |
Div. Sustainability Score | 9.24 | |
Div.Growth Potential Score | 4.12 | |
Div. Directional Score | 6.68 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
3606.HK | Ex Dividend Knight | 2023-05-23 | Annually | 0 | 0.00% | |
1599.HK | Ex Dividend Junior | 2023-05-31 | Annually | 0 | 0.00% | |
0636.HK | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
9982.HK | Ex Dividend Knight | 2023-12-12 | Semi-Annually | 0 | 0.00% | |
2189.HK | Ex Dividend Knight | 2023-08-16 | Semi-Annually | 0 | 0.00% | |
1184.HK | Ex Dividend Knight | 2023-09-21 | Semi-Annually | 0 | 0.00% | |
0251.HK | Ex Dividend Junior | 2023-09-20 | Semi-Annually | 0 | 0.00% | |
3900.HK | Ex Dividend Junior | 2023-06-20 | Sporadic | 0 | 0.00% | |
1760.HK | Ex Dividend Junior | 2023-06-01 | Annually | 0 | 0.00% | |
0798.HK | Ex Dividend Junior | 2023-06-20 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.317 | 1.500 | 3.67 | 5.50 | [0 - 0.5] |
returnOnAssetsTTM | 0.156 | 1.200 | 4.79 | 5.75 | [0 - 0.3] |
returnOnEquityTTM | 0.268 | 1.500 | 8.13 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.397 | 0.800 | 8.01 | 6.41 | [1 - 3] |
quickRatioTTM | 0.869 | 0.800 | 9.59 | 7.67 | [0.8 - 2.5] |
cashRatioTTM | 0.387 | 1.500 | 8.96 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.205 | -1.500 | 6.59 | -9.88 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.894 | 2.00 | 9.37 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.505 | 2.00 | 9.25 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.329 | -1.500 | 8.68 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.792 | 1.000 | 0.132 | 0.132 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.443 | 1.000 | 3.13 | 3.13 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.641 | 1.000 | 7.55 | 7.55 | [0.2 - 2] |
assetTurnoverTTM | 0.494 | 0.800 | -0.0406 | -0.0325 | [0.5 - 2] |
Total Score | 9.24 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 5.16 | 1.000 | 9.58 | 0 | [1 - 100] |
returnOnEquityTTM | 0.268 | 2.50 | 8.80 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.505 | 2.00 | 9.50 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.894 | 2.00 | 9.37 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0783 | 1.500 | -2.81 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.266 | 1.000 | 5.85 | 0 | [0.1 - 0.5] |
Total Score | 4.12 |
YiChang HEC ChangJiang
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic diseases, and cardiovascular diseases in the People's Republic of China. It also manufactures and sells active pharmaceutical ingredients; researches and develops medical devices and drugs, as well as biotechnology; and provides medical consulting services. The company sells its products to hospitals and medical institutions through a network of distributors. It has a strategic cooperation framework agreement with Alibaba Health Technology (China) Limited to carry out influenza special projects; Jointown Pharmaceutical Group Co., Ltd.; Guangdong Yihao Pharmaceutical Co., Ltd.; and Shenzhen HEC Industrial Development Co., Ltd, as well as strategic cooperative partnership with China National Accord Medicines Corporation Ltd. The company was formerly known as Yichang Changjiang Pharmaceutical Company Limited and changed its name to YiChang HEC ChangJiang Pharmaceutical Co., Ltd. in May 2015. The company was incorporated in 2001 and is based in Yichang, China. YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a subsidiary of Guangdong HEC Technology Holding Co., Ltd.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico